Cerebral Small Vessel Disease (CSVD)

Cerebral small vessel disease, or CSVD, is an umbrella term for conditions affecting the brain's smallest blood vessels. It can cause small deep strokes and changes in white matter. Depending on its extent and cause, it may affect thinking, movement and independence. Sometimes changes are found on MRI before there are obvious symptoms.

Terms such as white-matter hyperintensities, lacunes and microbleeds describe imaging findings, not a single diagnosis. Their meaning depends on the person's age, symptoms and medical history. European Stroke Organisation guidance

Common, sporadic CSVD becomes more frequent with age and is associated with vascular risk factors such as hypertension. It usually cannot be traced to one disease-causing gene. Care includes assessment of those risks and the symptoms or stroke history involved. An incidental MRI finding and a previous symptomatic stroke are different clinical situations. Covert CSVD guidance

Inherited forms may result from a variant in a single gene. Earlier symptoms, a family history, or features outside the brain can prompt genetic assessment, although the absence of family history does not exclude a genetic cause. Testing is most useful when guided by clinical assessment and genetic counselling. Genetic CSVD guide

CADASIL is associated with pathogenic NOTCH3 variants. COL4A1/COL4A2-related disorders affect type IV collagen and can involve the brain and other organs.

Other causes include HTRA1-related disease: variants in both copies can cause CARASIL, while some variants in one copy cause dominant small vessel disease. GLA variants cause Fabry disease, a multisystem condition that can include cerebrovascular involvement. Certain TREX1 variants cause retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. These conditions have different inheritance patterns, investigations and care needs; they should not be grouped under a single treatment claim. Inherited disease overview

A neurological assessment may combine examination, MRI, vascular risk assessment, cognitive testing and, where indicated, genetic testing. Disease-specific investigations are important when inherited CSVD is suspected. Diagnostic and management recommendations

Current care aims to reduce avoidable risk, treat symptoms and support function. It can involve blood-pressure care, smoking cessation, rehabilitation and support for cognition or mood. Medicines depend on the diagnosis and clinical history; an MRI finding alone does not mean everyone needs aspirin. Evidence for covert CSVD care

CSVD Therapeutics focuses on inherited disease, connecting patient experience with experimental therapeutic development. Our gene and RNA therapies, gene-editing concepts and drug-repurposing work are under development; the steps from a laboratory result to a patient study include delivery, safety and evidence of meaningful biological effects.

Therapeutic development explains the tools and roadmap. Sheffield Multicentre Research describes genetic studies, observational cohorts and clinical trials, with each study's local and national roles distinguished. Meet the leadership team or connect with us about research or family priorities.